DOCSLIB.ORG

View Library

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Toronto Forensic Library Index Number Compound Name Index Number Compound Name 1 Hexane 29 a-Caryophyllene, 60%; a- 2 Hexane Humulene, 60% 3 Heptane 30 b-Humulene; (E,E)-1,4,4- 4 Heptane Trimethyl-8-methylene-1,5- 5 Nonadecane cycloundecadiene 6 Docosane 31 b-Caryophyllene; 4,11,11- 7 Tricosane Trimethyl-8- 8 Tetracosane methylenebicyclo[7.2.0]undec 9 Octacosane -4-ene 10 Triacontane 32 b-Carotene 11 Petroleum ether 33 Squalene 12 Petroleum ether 34 Benzene 13 Petroleum ether, 30-60 35 Benzene 14 Hexane + petroleum ether 36 Toluene 15 2,2,4-Trimethylpentane; 37 Toluene Isooctane 38 Toluene + hexane, 1:1 16 Paraffin oil, white, light 39 p-Cymene; 4-Isopropyltoluene 17 Isoprene; 2-Methyl-1,3- 40 Xylenes butadiene 41 Xylenes 18 Isoprene; 2-Methyl-1,3- 42 Mesitylene; 1,3,5- butadiene Trimethylbenzene 19 Myrcene; 2-Methyl-6- 43 1-Phenyl-1-propene; 1- methylene-2,7-octadiene Propenylbenzene 20 Cyclohexane 44 Allylbenzene; 3-Phenyl-1- 21 Cyclohexane propene 22 (+)-Limonene; (+)-p-Mentha- 45 1-Phenylcyclohexene 1,8-diene, 97% 46 Biphenyl; Diphenyl 23 (-)-Limonene; (-)-p-Mentha- 47 o-Terphenyl 1,8-diene, 92% 48 m-Terphenyl 24 a-Terpinene; 1-Isopropyl-4- 49 p-Terphenyl methyl-1,3-cyclohexadiene; p- 50 Tetraphenylethylene Mentha-1,3-diene 51 Indene, 99+% 25 g-Terpinene; 1-Isopropyl-4- 52 Acenaphthene methyl-1,4-cyclohexadiene; p- 53 Pyrene Mentha-1,4-diene 54 Iodomethane; Methyl iodide 26 (+)-a-Pinene; (+)-2,6,6- 55 Iodoethane; Ethyl iodide Trimethylbicyclo[3.1.1]hept-2- 56 1-Chlorobutane; Butyl ene chloride 27 (-)-b-Pinene; (1S)-(-)-6,6- 57 1-Chlorobutane; Butyl Dimethyl-2- chloride methylenebicyclo[3.1.1]hepta 58 1-Bromobutane; Butyl ne bromide 28 Camphene, 80%, remainder 59 1-Chlorohexane; Hexyl tricyclene chloride Toronto Forensic Library, page 1 of 61 Index Number Compound Name Index Number Compound Name 60 Dichloromethane; Methylene 100 1-Octadecanol; Stearyl chloride alcohol 61 Dichloromethane; Methylene 101 2-Methyl-1-propanol; Isobutyl chloride alcohol 62 Dichloromethane; Methylene 102 2-Methyl-1-propanol; Isobutyl chloride alcohol 63 Diiodomethane; Methylene 103 2-Methyl-1-butanol iodide 104 2-Methyl-1-butanol 64 1,2-Dichloroethane; Ethylene 105 3-Methyl-1-butanol; Isoamyl dichloride alcohol 65 1,2-Dichloroethane; Ethylene 106 3-Methyl-1-butanol; Isoamyl dichloride alcohol 66 Chloroform 107 3-Methyl-1-butanol; Isoamyl 67 Chloroform alcohol 68 Petroleum ether + chloroform, 108 3-Methyl-1-butanol; Isoamyl 3:1 alcohol 69 Carbon tetrachloride 109 2-Methyl-1-pentanol 70 Carbon tetrachloride 110 2-Propanol; Isopropyl alcohol 71 1,1,1-Trichloroethane 111 2-Propanol; Isopropyl alcohol 72 1,1,1-Trichloroethane 112 2-Butanol 73 Halothane; 2-Bromo-2-chloro- 113 2-Butanol 1,1,1-trifluoroethane 114 2-Pentanol 74 Allyl chloride; 1-Chloro-2- 115 3-Pentanol propene 116 3-Methyl-2-butanol 75 Tetrachloroethylene 117 4-Methyl-2-pentanol 76 Chlorobenzene 118 2-Methyl-2-propanol; t-Butyl 77 Bromobenzene alcohol 78 Benzyl chloride; a- 119 3-Methyl-3-pentanol Chlorotoluene 120 3-Methyl-3-pentanol 79 (2-Bromoethyl)benzene; 121 1,2-Propanediol; Propylene Phenethyl bromide glycol 80 2-Bromo-1-phenylpropane 122 1,2-Propanediol; Propylene 81 1,4-Dichlorobenzene glycol 82 Methanol; Methyl alcohol 123 Citronellol; 3,7-Dimethyl-6- 83 Methanol; Methyl alcohol octen-1-ol 84 Methanol + methylene 124 Dihydrolinalool; 3,7-Dimethyl- chloride, 1:1 6-octen-3-ol 85 Chloroform + methanol, 3:1 125 Linalool; 3,7-Dimethyl-1,6- 86 Sodium methylate; Sodium octadien-3-ol methoxide 126 Geraniol; 3,7-Dimethyl-2,6- 87 Ethanol; Ethyl alcohol octadien-1-ol, 71% 88 Ethanol; Ethyl alcohol 127 Cyclohexanol 89 Ethanol, 40%; Ethyl alcohol, 128 l-Menthol; (-)-p-Menthan-3-ol 40% 129 Terpineol; p-Menth-1-en-8-ol 90 1-Butanol; Butyl alcohol 130 (-)-Carveol; (-)-p-Mentha-6,8- 91 1-Butanol; Butyl alcohol dien-2-ol 92 1-Pentanol; Amyl alcohol 131 Terpin hydrate; p-Menthane- 93 1-Hexanol; Hexyl alcohol, 1,8-diol .H2O 98% 132 Dihydropineol; 2,6,6- 94 1-Heptanol Trimethylbicyclo[3.1.1]heptan 95 1-Octanol; Octyl alcohol ol 96 1-Octanol; Capryl alcohol 133 Borneol; 1,7,7- 97 1-Decanol; Decyl alcohol Trimethylbicyclo[2.2.1]heptan- 98 1-Dodecanol; Dodecyl alcohol 2-ol, endo- 99 1-Hexadecanol; Cetyl alcohol Toronto Forensic Library, page 2 of 61 Index Number Compound Name Index Number Compound Name 134 Fenchyl alcohol; 1,3,3- 174 Dextrose + mannitol, 1:1 Trimethylbicyclo[2.2.1]heptan- 175 L-(+)-Rhamnose .H2O 2-ol 176 D-(+)-Mannose 135 Cedrol; 2,6,6,8- 177 D-(+)-Galactose Tetramethyltricyclo[5.3.1.0(1,5 178 L-(-)-Sorbose )]undecan-8-ol 179 D-(-)-Fructose 136 Inositol; myo-Inositol 180 Fructose + xylose, 1:1 137 Inositol + sodium bicarbonate, 181 Fructose + mannitol + xylose, 1:1 1:1:1 138 2-Chloroethanol 182 Fructose + mannitol + xylose, 139 1-Chloro-2-propanol 1:1:1 140 1,3-Dichloro-2-propanol 183 Maltitol; 4-O-a- 141 1,1,1-Trichloro-2-methyl-2- Glucopyranosyl-D-glucitol propanol 184 Lactose 142 Ethchlorvynol; 1-Chloro-3- 185 D-(+)-Lactose ethyl-1-penten-4-yn-3-ol 186 Lactose 143 Glycerin; Glycerol; 1,2,3- 187 Lactose Propanetriol 188 D-(+)-Lactose .H2O 144 Glycerin; Glycerol; 1,2,3- 189 Lactose + inositol, 1:1 Propanetriol 190 Lactose + mannitol, 1:1 145 Erythritol, meso- 191 Dextrose + lactose, 1:1 146 L-(-)-Arabinitol; Arabitol 192 Dextrose + inositol + lactose, 147 Adonitol; Ribitol 1:1:1 148 Xylitol 193 Lactulose 149 Sorbitol 194 D-(+)-Turanose; 3-O-a-D- 150 Sorbitol + mannitol, 4:1 Glucopyranosyl-D-fructose 151 Mannitol 195 D-Cellobiose 152 Mannitol 196 Palatinose; 6-O-a-D- 153 Mannite conoscenti; Mannitol Glucopyranosyl-D- 154 Mannitol + sodium fructofuranose bicarbonate, 1:1 197 b-Gentiobiose 155 Mannitol + sodium 198 D-(+)-Trehalose.2H2O bicarbonate, 1:1 199 Sucrose 156 Inositol + mannitol, 1:1 200 Sucrose 157 Inositol + mannitol, 1:1 201 Sucrose + sodium 158 Inositol + mannitol, 1:1 bicarbonate, 2:1 159 Dulcitol; Galactitol 202 Inositol + sucrose, 1:1 160 D-(-)-Erythrose, 85% 203 Mannitol + sucrose, 1:1 161 L-(+)-Arabinose 204 Dextrose + sucrose, 1:1 162 D-Lyxose 205 Lactose + sucrose, 1:1 163 D-(+)-Xylose 206 Maltose .H2O 164 D-2-Deoxyribose 207 a-D-Melibiose .H2O 165 D-(-)-Ribose 208 D-(+)-Melezitose .H2O 166 b-D-Allose 209 Raffinose 167 a-L-(-)-Fucose; 6-Deoxy-L- 210 Dextrin galactose 211 a-Chloralose 168 a-L-(-)-Fucose; 6-Deoxy-L- 212 Dichloromethyl methyl ether galactose 213 Diethyl ether; Ethyl ether 169 Dextrose, anhydrous; D- 214 Diethyl ether; Ethyl ether Glucose, anhydrous 215 Diethyl ether; Ethyl ether 170 Dextrose; D-Glucose 216 Petroleum ether + diethyl 171 Dextrose + sodium ether, 4:1 bicarbonate, 1:1 217 Methoxyflurane; 2,2-Dichloro- 172 Dextrose + inositol, 1:1 1,1-difluoro-1-methoxyethane 173 Dextrose + inositol, 1:1 Toronto Forensic Library, page 3 of 61 Index Number Compound Name Index Number Compound Name 218 Ethylene glycol monomethyl 253 Catechol; 1,2-Benzenediol ether; 2-Methoxyethanol 254 Resorcinol; 1,3-Benzenediol 219 2-Ethoxyethanol; Cellosolve 255 2-Methylresorcinol; 2,6- 220 2,2'-Oxydiethanol; Diethylene Dihydroxytoluene glycol 256 4-Hexylresorcinol 221 2-(2-Ethoxyethoxy)ethanol; 257 Orcinol .H2O; 5- Carbitol Methylresorcinol .H2O 222 Tetraethylene glycol 258 Olivetol; 5-Pentylresorcinol 223 a-Pinene oxide 259 4,6-Di-t-butylresorcinol 224 Tetrahydrofuran 260 Hydroquinone; 1,4- 225 Tetrahydrofuran Benzenediol 226 2,5-Dimethoxytetrahydrofuran 261 Methylhydroquinone; 2- 227 2,5-Diethoxytetrahydrofuran Methyl-1,4-benzenediol 228 Cineole; Eucalyptol; 1,8- 262 t-Butylhydroquinone Epoxy-p-menthane 263 Bromohydroquinone; 2- 229 1,4-Dioxane Bromo-1,4-benzenediol 230 Paraldehyde; 2,4,6-Trimethyl- 264 Pyrogallol; 1,2,3-Benzenetriol 1,3,5-trioxane 265 Phloroglucinol; 1,3,5- 231 18-Crown-6 Benzenetriol 232 Phenol 266 1-Naphthol 233 Guaiacol; 2-Methoxyphenol 267 2-Naphthol 234 4-Phenylphenol; 4- 268 2-Naphthol Hydroxybiphenyl 269 1,3-Dihydroxynaphthalene; 235 4-Chlorophenol 1,3-Naphthalenediol 236 2,6-Dimethoxyphenol 270 2,7-Dihydroxynaphthalene; 237 4-Chloro-3-methylphenol; 4- 2,7-Naphthalenediol Chloro-m-cresol 271 2-Phenylphenol; 2- 238 4-Chloro-3-methylphenol; 4- Hydroxybiphenyl Chloro-m-cresol 272 Diethylstilbestrol; 3,4-Bis(4- 239 Eugenol; 4-Allyl-2- hydroxyphenyl)-3-hexene methoxyphenol 273 Diethylstilbestrol diphosphate, 240 Carvacrol; 2-p-Cymenol; 5- tetrasodium salt; Fosfestrol, Isopropyl-2-methylphenol tetrasodium salt 241 3-Ethoxy-4-methoxyphenol 274 Diethylstilbestrol dipropionate 242 Sesamol; 3,4- 275 Dienestrol; 3,4-Bis(4- Methylenedioxyphenol hydroxyphenyl)-2,4- 243 Cannabichromene; 2-Methyl- hexadiene 2-(4-methyl-3-pentenyl)-7- 276 Nordihydroguaiaretic acid; pentyl-2H-1-benzopyran-5-ol 2,3-Bis(3,4- 244 4-Chloro-3,5-xylenol dihydroxybenzyl)butane 245 6-Chlorothymol; 4-Chloro-2- 277 Hexachlorophene; 2,2'- isopropyl-5-methylphenol Methylenebis(3,4,6- 246 2,6-Di-t-butyl-4-methylphenol; trichlorophenol) BHT 278 Benzyl alcohol 247 Butylated hydroxyanisole; 279 1-Phenyl-1-propanol; a- BHA Ethylbenzyl alcohol 248 Butylated hydroxyanisole; 280 Triphenylmethanol BHA 281 Saligenin; 2-Hydroxybenzyl 249 3,5-Di-t-butyl-4- alcohol hydroxyanisole 282 2-Methoxybenzyl alcohol 250 Probucol; 4,4'- 283 2-Ethoxybenzyl alcohol (Isopropylidenedithio)bis(2,6- 284 Salicin; 2- di-t-butylphenol) (Hydroxymethyl)phenyl-b-D- 251 2,3,4,5-Tetrachlorophenol glucopyranose 252 Pentachlorophenol Toronto Forensic Library, page 4 of 61 Index Number Compound Name Index Number Compound Name 285 9H-Xanthen-9-ol; 9- 320 Cinnamyl alcohol; 3-Phenyl-2- Hydroxyxanthene propen-1-ol 286 3-Methoxybenzyl alcohol 321 Isosafrole glycol; 1-(3,4- 287 4-Isopropylbenzyl alcohol Methylenedioxyphenyl)-1,2-
Recommended publications
  • Minnesota Statutes 1979 Supplement

    Minnesota Statutes 1979 Supplement

    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
  • Amplification of Oxidative Stress by a Dual Stimuli-Responsive Hybrid Drug

    Amplification of Oxidative Stress by a Dual Stimuli-Responsive Hybrid Drug

    ARTICLE Received 11 Jul 2014 | Accepted 12 Mar 2015 | Published 20 Apr 2015 DOI: 10.1038/ncomms7907 Amplification of oxidative stress by a dual stimuli-responsive hybrid drug enhances cancer cell death Joungyoun Noh1, Byeongsu Kwon2, Eunji Han2, Minhyung Park2, Wonseok Yang2, Wooram Cho2, Wooyoung Yoo2, Gilson Khang1,2 & Dongwon Lee1,2 Cancer cells, compared with normal cells, are under oxidative stress associated with the increased generation of reactive oxygen species (ROS) including H2O2 and are also susceptible to further ROS insults. Cancer cells adapt to oxidative stress by upregulating antioxidant systems such as glutathione to counteract the damaging effects of ROS. Therefore, the elevation of oxidative stress preferentially in cancer cells by depleting glutathione or generating ROS is a logical therapeutic strategy for the development of anticancer drugs. Here we report a dual stimuli-responsive hybrid anticancer drug QCA, which can be activated by H2O2 and acidic pH to release glutathione-scavenging quinone methide and ROS-generating cinnamaldehyde, respectively, in cancer cells. Quinone methide and cinnamaldehyde act in a synergistic manner to amplify oxidative stress, leading to preferential killing of cancer cells in vitro and in vivo. We therefore anticipate that QCA has promising potential as an anticancer therapeutic agent. 1 Department of Polymer Á Nano Science and Technology, Polymer Fusion Research Center, Chonbuk National University, Backje-daero 567, Jeonju 561-756, Korea. 2 Department of BIN Convergence Technology, Chonbuk National University, Backje-daero 567, Jeonju 561-756, Korea. Correspondence and requests for materials should be addressed to D.L. (email: [email protected]). NATURE COMMUNICATIONS | 6:6907 | DOI: 10.1038/ncomms7907 | www.nature.com/naturecommunications 1 & 2015 Macmillan Publishers Limited.
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts

    Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts

    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • MSM Cross Reference Antihistamine Decongestant 20100701 Final Posted

    MSM Cross Reference Antihistamine Decongestant 20100701 Final Posted

    MISSISSIPPI DIVISION OF MEDICAID Antihistamine/Decongestant Product and Active Ingredient Cross-Reference List The agents listed below are the antihistamine/decongestant drug products listed in the Mississippi Medicaid Preferred Drug List (PDL). This is a cross-reference between the drug product name and its active ingredients to reference the antihistamine/decongestant portion of the PDL. For more information concerning the PDL, including non- preferred agents, the OTC formulary, and other specifics, please visit our website at www.medicaid.ms.gov. List Effective 07/16/10 Therapeutic Class Active Ingredients Preferred Non-Preferred ANTIHISTAMINES - 1ST GENERATION BROMPHENIRAMINE MALEATE BPM BROMAX BROMPHENIRAMINE MALEATE J-TAN PD BROMSPIRO LODRANE 24 LOHIST 12HR VAZOL BROMPHENIRAMINE TANNATE BROMPHENIRAMINE TANNATE J-TAN P-TEX BROMPHENIRAMINE/DIPHENHYDRAM ALA-HIST CARBINOXAMINE MALEATE CARBINOXAMINE MALEATE PALGIC CHLORPHENIRAMINE MALEATE CHLORPHENIRAMINE MALEATE CPM 12 CHLORPHENIRAMINE TANNATE ED CHLORPED ED-CHLOR-TAN MYCI CHLOR-TAN MYCI CHLORPED PEDIAPHYL TANAHIST-PD CLEMASTINE FUMARATE CLEMASTINE FUMARATE CYPROHEPTADINE HCL CYPROHEPTADINE HCL DEXCHLORPHENIRAMINE MALEATE DEXCHLORPHENIRAMINE MALEATE DIPHENHYDRAMINE HCL ALLERGY MEDICINE ALLERGY RELIEF BANOPHEN BENADRYL BENADRYL ALLERGY CHILDREN'S ALLERGY CHILDREN'S COLD & ALLERGY COMPLETE ALLERGY DIPHEDRYL DIPHENDRYL DIPHENHIST DIPHENHYDRAMINE HCL DYTUSS GENAHIST HYDRAMINE MEDI-PHEDRYL PHARBEDRYL Q-DRYL QUENALIN SILADRYL SILPHEN DIPHENHYDRAMINE TANNATE DIPHENMAX DOXYLAMINE SUCCINATE
  • Poisons and Narcotic Drugs (Amendment) Ordinance 1988

    Poisons and Narcotic Drugs (Amendment) Ordinance 1988

    AUSTRALIAN CAPITAL TERRITORY Poisons and Narcotic Drugs (Amendment) Ordinance 1988 No. 96 of 1988 I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Ordinance under the Seat of Government (Administration) Act 1910. Dated 15 December 1988 N. M. STEPHEN Governor-General By His Excellency’s Command, CLYDE HOLDING Minister of State for the Arts and Territories An Ordinance to amend the Poisons and Narcotic Drugs Ordinance 1978 Short title 1. This Ordinance may be cited as the Poisons and Narcotic Drugs (Amendment) Ordinance 1988.1 Commencement 2. This Ordinance commences on such date as is fixed by the Minister by notice in the Gazette. Principal Ordinance 3. In this Ordinance, “Principal Ordinance” means the Poisons and Narcotic Drugs Ordinance 1978.2 (Ord. 79/88)—Cat. No. Authorised by the ACT Parliamentary Counsel—also accessible at www.legislation.act.gov.au 2 Poisons and Narcotic Drugs (Amendment) No. 96, 1988 Substances to which Division applies 4. Section 27B of the Principal Ordinance is amended by adding at the end the following paragraphs: “; (f) follicle stimulating hormone; (g) luteinising hormone; (h) thalidomide.”. Grant of authorisation 5. Section 27E of the Principal Ordinance is amended— (a) by omitting from paragraph (1) (a) “or cyclofenil” and substituting “, cyclofenil, follicle stimulating hormone or luteinising hormone”; (b) by omitting from paragraph (1) (b) “and”; and (c) by adding at the end of subsection (1) the following word and paragraph: “; and (d) in the case of an application that relates to thalidomide— the applicant is a specialist physician with no less than 5 years’ experience in the treatment of erythema nodosum leprosum.”.
  • Programme & Abstracts

    Programme & Abstracts

    The 57th Annual Meeting of the International Association of Forensic Toxicologists. 2nd - 6th September 2019 BIRMINGHAM, UK The ICC Birmingham Broad Street, Birmingham B1 2EA Programme & Abstracts 1 Thank You to our Sponsors PlatinUm Gold Silver Bronze 2 3 Contents Welcome message 5 Committees 6 General information 7 iCC maps 8 exhibitors list 10 Exhibition Hall 11 Social Programme 14 opening Ceremony 15 Schedule 16 Oral Programme MONDAY 2 September 19 TUESDAY 3 September 21 THURSDAY 5 September 28 FRIDAY 6 September 35 vendor Seminars 42 Posters 46 oral abstracts 82 Poster abstracts 178 4 Welcome Message It is our great pleasure to welcome you to TIAFT Gala Dinner at the ICC on Friday evening. On the accompanying pages you will see a strong the UK for the 57th Annual Meeting of scientific agenda relevant to modern toxicology and we The International Association of Forensic thank all those who submitted an abstract and the Toxicologists Scientific Committees for making the scientific programme (TIAFT) between 2nd and 6th a success. Starting with a large Young Scientists September 2019. Symposium and Dr Yoo Memorial plenary lecture by Prof Tony Moffat on Monday, there are oral session topics in It has been decades since the Annual Meeting has taken Clinical & Post-Mortem Toxicology on Tuesday, place in the country where TIAFT was founded over 50 years Human Behaviour Toxicology & Drug-Facilitated Crime on ago. The meeting is supported by LTG (London Toxicology Thursday and Toxicology in Sport, New Innovations and Group) and the UKIAFT (UK & Ireland Association of Novel Research & Employment/Occupational Toxicology Forensic Toxicologists) and we thank all our exhibitors and on Friday.
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Cinnamaldehyde Induces Release of Cholecystokinin and Glucagon-Like

    Cinnamaldehyde Induces Release of Cholecystokinin and Glucagon-Like

    animals Article Cinnamaldehyde Induces Release of Cholecystokinin and Glucagon-Like Peptide 1 by Interacting with Transient Receptor Potential Ankyrin 1 in a Porcine Ex-Vivo Intestinal Segment Model Elout Van Liefferinge 1,* , Maximiliano Müller 2, Noémie Van Noten 1 , Jeroen Degroote 1 , Shahram Niknafs 2, Eugeni Roura 2 and Joris Michiels 1 1 Laboratory for Animal Nutrition and Animal Product Quality (LANUPRO), Department of Animal Sciences and Aquatic Ecology, Ghent University, 9000 Ghent, Belgium; [email protected] (N.V.N.); [email protected] (J.D.); [email protected] (J.M.) 2 Centre for Nutrition and Food Sciences, Queensland Alliance for Agriculture and Food Innovation, The University of Queensland, St. Lucia, QLD 4072, Australia; [email protected] (M.M.); [email protected] (S.N.); [email protected] (E.R.) * Correspondence: [email protected] Simple Summary: The gut is able to “sense” nutrients and release gut hormones to regulate diges- tive processes. Accordingly, various gastrointestinal cell types possess transient receptor potential channels, cation channels involved in somatosensation, thermoregulation and the sensing of pungent and spicy substances. Recent research shows that both channels are expressed in enteroendocrine Citation: Van Liefferinge, E.; Müller, M.; Van Noten, N.; Degroote, J.; cell types responsible for the release of gut peptide hormones such as Cholecystokinin (CCK) and Niknafs, S.; Roura, E.; Michiels, J. Glucagon-like Peptide-1 (GLP-1). A large array of herbal compounds, used in pig nutrition mostly for Cinnamaldehyde Induces Release of their antibacterial and antioxidant properties, are able to activate these channels. Cinnamaldehyde, Cholecystokinin and Glucagon-Like occurring in the bark of cinnamon trees, acts as an agonist of Transient Receptor Potential Ankyrin 1 Peptide 1 by Interacting with (TRPA1)-channel.
  • CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun

    CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun

    CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.